The global cardiovascular stents market is undergoing a transformative shift, driven by increasing clinical complexity, advancements in material sciences, and rising prevalence of lifestyle-related cardiovascular diseases. Stents, once seen as basic scaffolding devices, are now evolving into precision-engineered tools tailored to complex anatomies, high-risk patient populations, and minimally invasive delivery systems. According to Persistence Market Research, the market is projected to grow from US$ 12.7 Bn in 2025 to US$ 23.1 Bn by 2032, expanding at a CAGR of 8.9% during the forecast period.
This robust growth is primarily attributed to the surge in percutaneous coronary interventions (PCI), growing geriatric populations, and the increasing demand for drug-eluting and bioresorbable stents. Among the product segments, coronary stents are anticipated to dominate with a 67.3% share in 2025, while North America is expected to lead geographically, driven by technological innovation, strong reimbursement policies, and a high volume of interventional cardiology procedures.
Key Highlights from the Report:
• Surge in lifestyle-related cardiac events is propelling emergency PCI interventions.
• Increasing investment in dual-therapy stents combining anti-proliferative and anti-thrombotic agents is creating new avenues.
• Surging clinical trial data is opening doors for niche indications such as left main disease and bifurcations.
• Innovation in biodegradable polymers and nanocoatings is offering IP-rich commercialization avenues.
• Coronary stents are predicted to account for nearly 67.3% share in 2025, enabling faster revascularization.
• Drug-eluting stents continue to dominate due to superior outcomes and cost-effectiveness.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35535
Market Segmentation:
By Procedure Type
The cardiovascular stents market is bifurcated into coronary stenting and peripheral stenting. Coronary stenting dominates the landscape, driven by its minimally invasive nature, faster recovery times, and proven clinical efficacy in managing coronary artery disease. Particularly beneficial for elderly and comorbid patients, coronary stents enable quick symptom relief and reduce the need for complex surgeries such as coronary artery bypass grafting (CABG).
On the other hand, peripheral stenting is gaining traction due to the rising incidence of Peripheral Artery Disease (PAD). PAD affects over 230 million individuals globally, as per 2023 data. Peripheral stents serve as a cost-effective and less invasive alternative to traditional open vascular surgery, especially in diabetic and aging populations prone to limb ischemia and mobility challenges.
By Stent Type
By stent type, the market is segmented into Drug-Eluting Stents (DES), bare-metal stents, bioresorbable stents, and others. Among these, DES are projected to command 65.2% of the market by 2025, thanks to their ability to reduce restenosis and the need for repeat revascularizations. These stents release antiproliferative drugs to prevent neointimal hyperplasia, a common cause of stent failure.
Bioresorbable stents, although still emerging, are gaining acceptance, particularly for younger patients or those requiring future interventions. Made from biodegradable materials such as magnesium alloys or polymers, these stents dissolve over time, restoring natural vessel flexibility and reducing long-term complications like thrombosis or inflammation.
Regional Insights:
North America
North America is expected to hold around 30.6% of the global market share by 2025, driven by an aging population, increasing CAD prevalence, and rapid adoption of next-gen stent technologies. In the U.S. alone, CAD claims over 370,000 lives annually, according to the CDC. This demographic trend, combined with favorable reimbursement policies and technological advancements in DES and robotic PCI systems, positions the region as the market leader.
Europe
Europe is navigating a transitional period due to the implementation of the EU Medical Device Regulation (MDR). While this has slowed product approvals, countries like Germany remain leaders in adopting imaging-assisted stenting (IVUS, OCT) and advanced DES technologies. The region also shows strong clinical research activity, though fragmented regulatory systems have somewhat tempered the pace of new device adoption across the EU bloc.
Asia Pacific
The Asia Pacific region is witnessing rapid expansion fueled by healthcare reforms, growing access to PCI, and local manufacturing strengths. China has seen a surge in procedures due to its Volume-Based Procurement (VBP) policy, making stents more affordable. Meanwhile, India’s price caps on cardiovascular stents continue to reshape market dynamics, giving rise to domestic players such as Meril Life Sciences and Sahajanand Medical Technologies, who offer competitively priced, clinically validated alternatives to Western brands.
Market Drivers
The primary driver of the cardiovascular stents market is the global burden of cardiovascular diseases (CVDs). As ischemic heart disease continues to lead mortality statistics—claiming over 9 million lives annually—the demand for stent-based interventions has escalated. Aging populations, rising obesity, diabetes prevalence, and increasing sedentary lifestyles contribute to arterial blockages requiring interventional management. Stents, particularly DES, remain a frontline solution due to their minimally invasive nature and rapid recovery profile.
Additionally, the shift towards value-based healthcare and the adoption of robotic-assisted PCI systems are driving hospitals and cardiac centers to invest in advanced stent platforms. As per data from Persistence Market Research, novel device introductions such as ultra-thin strut DES and dual-therapy platforms are expanding indications and improving clinical outcomes across patient demographics.
Market Restraints
Despite the promising growth trajectory, several restraints hinder full-scale adoption of cardiovascular stents. One major concern is the risk of access-site complications, including bleeding, hematoma, and contrast-induced allergic reactions, particularly in elderly or high-risk populations. According to JACC: Cardiovascular Interventions, 6–8% of PCI procedures result in complications that prolong hospitalization or increase mortality.
Additionally, regulatory delays, especially in Europe post-MDR, and pricing pressures in developing countries like India and China are constraining profitability and delaying product launches. These dynamics are especially challenging for smaller companies trying to enter the market or scale up their operations amid increasing clinical and compliance burdens.
Market Opportunities
There is significant potential for growth in next-generation stents designed for small vessels, complex bifurcations, and high-risk patients. Innovations like magnesium-based bioresorbable scaffolds, nanocoatings, and dual-drug release platforms are expected to open new indications and improve patient compliance. Clinical studies like the MAGNITUDE trial underscore the effectiveness of these devices in reducing late stent thrombosis and encouraging vascular healing.
Furthermore, the integration of intravascular imaging and AI-assisted procedure planning represents a frontier for product differentiation. As hospitals increasingly focus on outcome-based reimbursement models, these advanced stents can reduce total procedural costs, readmissions, and adverse event rates. Companies that invest in IP-rich designs and clinical data will have a competitive edge in both developed and emerging markets.
Reasons to Buy the Report:
Gain data-backed insights into a market growing at 8.9% CAGR from 2025 to 2032.
Understand the impact of evolving technologies like bioresorbable stents and robotic PCI.
Identify market opportunities across emerging economies with evolving price regulations.
Access segmentation analysis by stent type, procedure, and region to plan your strategy.
Stay informed about key players and recent innovations disrupting the stent ecosystem.
Frequently Asked Questions (FAQs):
How Big is the Cardiovascular Stents Market in 2025 and what is its growth outlook?
What is the Projected Growth Rate of the Cardiovascular Stents Market from 2025 to 2032?
Who are the Key Players in the Global Cardiovascular Stents Market?
What is the Market Forecast for Cardiovascular Stents up to 2032?
Which Region is Estimated to Dominate the Industry through the Forecast Period?
Company Insights:
• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic plc
• Terumo Corporation
• Biotronik SE & Co. KG
• B. Braun Melsungen AG
• Cook Medical
• Cardinal Health, Inc.
• MicroPort Scientific Corporation
• C. R. Bard, Inc.
Recent Market Developments
• In January 2025, Bentley introduced two pioneering devices at the Leipzig Interventional Course: the BeGraft stent graft system and the BeFlared stent for FEVAR, both setting new benchmarks in bridging technology.
• In May 2024, Abbott launched the XIENCE Sierra everolimus-eluting stent in India after securing regulatory approval from the CDSCO, reflecting its strategy to deepen market penetration in emerging economies.
Conclusion
The cardiovascular stents market stands at a dynamic intersection of medical innovation, demographic trends, and healthcare policy evolution. With a compound annual growth rate of 8.9% through 2032, it offers significant opportunities for both established players and emerging innovators.
Read More Related Reports:




